IDEXX Laboratories Inc (IX1.BE)
| Previous close | 450.60 |
| Open | 453.40 |
| Bid | 456.30 x 0 |
| Ask | 457.50 x 0 |
| Day's range | 453.40 - 453.40 |
| 52-week range | 368.00 - 532.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes. The Catalyst Pancreatic Lipase Test will be available in the U.S. and Ca
- Business Wire
IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day
WESTBROOK, Maine, May 14, 2024--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon, Executive Vice President and Chief Financial Officer, and Michael Lane, Executive Vice President, General Manager, Reference Laboratories and Information Technology, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 29, 2024 from 10:55 am – 11:25 am (EDT).
- Business Wire
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine, May 01, 2024--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results.
